somerset pharmaceuticals, inc. , a wholly owned subsidiary of mylan inc. ,
received approval from the fda for emsam® transdermal
selegiline, on february 27 of 2006. Emsam® is the
first transdermal treatment for major depressive disorder. All aspects of the
emsam® product related to its design, chemistry,
manufacturing and controls were the result of the integration of the talents
and expertise of mti scientists. Emsam® is
manufactured by mti.
antidepressants increased the risk of suicidal thinking and behavior
(suicidality) in short-term studies in children and adolescents with major
depressive disorder (mdd) and other psychotic disorders. Anyone considering the
use of emsam® or other antidepressants in a child or
adolescent must balance this risk with the clinical need.
emsam® is not indicated for use in pediatric patients.
for additional details please see full prescribing information, including boxed
Molecular formula:HNO3 Molecular weight:63.01 CAS NO.:7697-37-2 Property:Pure nitric acid is colorless liquid with pungent odor,it's density is ...view details
high purity 99.9% Epichlorohydrin Properity it is the unstable colorless liquid,easy to volatilize, has with the chloroform, the ether similar ...view details
Poongsan manufactures semi-finished products and components used in the production of ammunition such as primers, fuses, bullet jacket cups, case ...view details
sending enquiry ....